Why the study?
Venous thromboembolism is a significant complication after allogeneic HCT, but the optimal timing of thromboprophylaxis remains uncertain given concurrent bleeding risks.
Can the HIGH-2-LOW risk assessment model predict incident venous thromboembolism in patients after allogeneic hematopoietic cell transplantation?
Can the HIGH-2-LOW risk assessment model predict incident venous thromboembolism in patients after allogeneic hematopoietic cell transplantation?
Answers are grounded in this paper and cite their sources.
The HIGH-2-LOW risk model successfully stratifies allogeneic HCT patients by VTE risk, identifying a high-risk group with a 10.3% incidence at 100 days who may benefit from early thromboprophylaxis.
Venous thromboembolism (VTE) after allogeneic hematopoietic cell transplantation (HCT) is a significant treatment-associated complication, although optimal timing of thromboprophylaxis remains uncertain when weighing concurrent risks of bleeding. We aimed to derive and internally validate a risk assessment model (RAM) using patients who underwent first allogeneic HCT from 2006 through 2015 (n = 1703). Index date was defined as the 30th day after transplant, at which point we estimated >75% of patients would have achieved platelet engraftment >50 × 109/L. Stepwise logistic regression modeling was used for model development, and internal validation was achieved by fitting a logistic regression model with 1000 bootstrapped resamples to estimate the optimism-corrected c-statistic. The final RAM, "HIGH-2-LOW," included 7 predictors obtained at 30 days after transplant: History of catheter-related deep venous thrombosis (DVT), Inpatient at day 30, Graft-versus-host disease grade 3 to 4, History of pulmonary embolism or lower-extremity DVT, Lymphoma diagnosis, Obesity with body mass index ≥35 kg/m2, and White blood cell count ≥11 × 109/L. Approximately 16% of patients were stratified as high risk, with incident VTE rate of 10.3% at 100 days compared with 1.5% for those at low risk. VTE odds ratios at 100 days were 5.87 (95% confidence interval [CI], 2.98-11.57) and 2.71 (95% CI, 1.38-5.35) in the high- and intermediate-risk vs low-risk groups, respectively. HIGH-2-LOW model serves as a novel and potentially clinically meaningful tool to identify high-risk allogeneic HCT patients who may benefit from early thromboprophylaxis after platelet engraftment.
No takes yet. Share an insight, caveat, or question.
Martens et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: